EU Pharmaceuticals

In addition to the trading of generics, HAEMATO imports pharmaceuticals from other European countries. The pharmaceuticals find their way to the German patients through various channels: Either as a parallel import or re-import. What is crucial is that in any case it is an original product. The growing market share of imported drugs demonstrates their importance in the German healthcare system. In 2007 imported pharmaceuticals had a total market share of 8.9%. By 2010 this share increased to 11.8%.

In 2012 the German healthcare system spent around 2.9 billion euros on parallel imported pharmaceuticals. Europe-wide this figure amounted to 5.5 billion euros. Therefore the German healthcare system accounts for 53% of all imports followed by the UK with 15% and the Netherlands with 11%.

The product portfolio of HAEMATO includes over 750 import licenses that cover five major therapeutic areas:

  • Neurology
  • Oncology
  • Rheumatology
  • Urology

A detailed list of the various products, can be found here.


Die HAEMATO AG ist ein börsennotiertes pharmazeutisches Unternehmen mit Fo-kus auf die Wachstumsmärkte patentfreier und patentgeschützter Arzneimittel...


IFRS-Ergebnis Q1 2017, Umsatz 67,9 Mio. Euro (Vorjahresperiode: 67,9 Mio. Euro), EBIT 2,8 Mio. Euro (Vorjahresperiode: 3,5 Mio. Euro)...


2016: Vorläufiges IFRS-Ergebnis, Umsatzwachstum 20% auf 275,6 Mio. Euro, EBIT-Wachstum (operatives Ergebnis) 63% auf 13,4 Mio. Euro;...

Order service - Telephone: +49 30 677 98 67 60
Aktuelle News